CUE BIOPHARMA INC. -

Cue Biopharma Reports First Quarter 2022 Financial Results

10 May 2022 15:30:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference

10 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress

02 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting

15 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

26 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

20 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102

05 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

15 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit

06 Dec 2021 07:00:03 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

22 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

12 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

10 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases

21 Oct 2021 11:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting

04 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

28 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

21 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

09 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights

17 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

10 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference

03 Aug 2021 07:01:12 By Nasdaq GlobeNewswire